RARE - Ultragenyx Pharmaceutical Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
IPO Date: January 31, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $1.47B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.57 | 2.67%
Avg Daily Range (30 D): $0.76 | 4.02%
Avg Daily Range (90 D): $0.91 | 3.76%
Institutional Daily Volume
Avg Daily Volume: .64M
Avg Daily Volume (30 D): 5.06M
Avg Daily Volume (90 D): 2.88M
Trade Size
Avg Trade Size (Sh.): 69
Avg Trade Size (Sh.) (30 D): 113
Avg Trade Size (Sh.) (90 D): 87
Institutional Trades
Total Institutional Trades: 8,900
Avg Institutional Trade: $2.68M
Avg Institutional Trade (30 D): $3.81M
Avg Institutional Trade (90 D): $4.85M
Avg Institutional Trade Volume: .06M
Avg Institutional Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $4.91M
Avg Closing Trade (30 D): $12.01M
Avg Closing Trade (90 D): $13.26M
Avg Closing Volume: 107.91K
 
News
Oct 8, 2026 @ 1:49 PM
Ultragenyx to Sell Rare Pediatric Disease PRV for ...
Source: Na
Oct 6, 2026 @ 8:58 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Oct 6, 2026 @ 8:54 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Sep 3, 2026 @ 3:30 PM
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnin...
Source: Na
Sep 2, 2026 @ 12:00 PM
Amlogenyx to Present at the Wells Fargo 21Ë¢áµ...
Source: Not Specified
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-5.82 $-.9 $-1.84
Diluted EPS $-5.82 $-.9 $-1.84
Revenue $717.21M $214M $136M
Gross Profit
Net Income / Loss $-585.97M $-92M $-185M
Operating Income / Loss $-528.17M $-75M $-169M
Cost of Revenue
Net Cash Flow $-48M $-296M $M
PE Ratio    
Splits
Jan 17, 2014 15:47